Request Free Sample ×
Unnatural Amino Acids Market Research Report - Forecast till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Unnatural Amino Acids Market

ID: MRFR/Pharma/3479-CR
216 Pages
Vikita Thakur
Last Updated: January 16, 2026

Unnatural Amino Acids Market Research Report Information By Type (D-Amino Acids & Derivatives, DL-Amino Acids & Derivatives, B-Amino Acids & Derivatives, Cyclic Amino Acids & Derivatives, L-Amino Acid Derivatives, Gamma-Amino Butyric Acid {GABA}, Gamma-Amino-Beta-Hydroxybutyric Acid (GABOB), Synthetic-Amino Acids, Others), By Application (Liver Diseases, Cancer, Inflammatory Disease, Genetic Diseases), By End-User (Pharmaceutical & Biotechnological, Companies, Research Laboratories) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Unnatural Amino Acids Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Type (USD Billion)
  49.     4.1.1 D-Amino Acids & Derivatives
  50.     4.1.2 DL-Amino Acids & Derivatives
  51.     4.1.3 B-Amino Acids & Derivatives
  52.     4.1.4 Cyclic Amino Acids & Derivatives
  53.     4.1.5 L-Amino Acid Derivatives
  54.     4.1.6 Gamma-Amino Butyric Acid (GABA)
  55.     4.1.7 Gamma-Amino-Beta-Hydroxybutyric Acid (GABOB)
  56.     4.1.8 Synthetic-Amino Acids
  57.     4.1.9 Others
  58.   4.2 Healthcare, BY Application (USD Billion)
  59.     4.2.1 Liver Diseases
  60.     4.2.2 Cancer
  61.     4.2.3 Inflammatory Diseases
  62.     4.2.4 Genetic Diseases
  63.   4.3 Healthcare, BY End-User (USD Billion)
  64.     4.3.1 Pharmaceutical & Biotechnological Companies
  65.     4.3.2 Research Laboratories
  66.   4.4 Healthcare, BY Region (USD Billion)
  67.     4.4.1 North America
  68.       4.4.1.1 US
  69.       4.4.1.2 Canada
  70.     4.4.2 Europe
  71.       4.4.2.1 Germany
  72.       4.4.2.2 UK
  73.       4.4.2.3 France
  74.       4.4.2.4 Russia
  75.       4.4.2.5 Italy
  76.       4.4.2.6 Spain
  77.       4.4.2.7 Rest of Europe
  78.     4.4.3 APAC
  79.       4.4.3.1 China
  80.       4.4.3.2 India
  81.       4.4.3.3 Japan
  82.       4.4.3.4 South Korea
  83.       4.4.3.5 Malaysia
  84.       4.4.3.6 Thailand
  85.       4.4.3.7 Indonesia
  86.       4.4.3.8 Rest of APAC
  87.     4.4.4 South America
  88.       4.4.4.1 Brazil
  89.       4.4.4.2 Mexico
  90.       4.4.4.3 Argentina
  91.       4.4.4.4 Rest of South America
  92.     4.4.5 MEA
  93.       4.4.5.1 GCC Countries
  94.       4.4.5.2 South Africa
  95.       4.4.5.3 Rest of MEA
  96. 5 SECTION V: COMPETITIVE ANALYSIS
  97.   5.1 Competitive Landscape
  98.     5.1.1 Overview
  99.     5.1.2 Competitive Analysis
  100.     5.1.3 Market share Analysis
  101.     5.1.4 Major Growth Strategy in the Healthcare
  102.     5.1.5 Competitive Benchmarking
  103.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  104.     5.1.7 Key developments and growth strategies
  105.       5.1.7.1 New Product Launch/Service Deployment
  106.       5.1.7.2 Merger & Acquisitions
  107.       5.1.7.3 Joint Ventures
  108.     5.1.8 Major Players Financial Matrix
  109.       5.1.8.1 Sales and Operating Income
  110.       5.1.8.2 Major Players R&D Expenditure. 2023
  111.   5.2 Company Profiles
  112.     5.2.1 Ajinomoto Co., Inc. (JP)
  113.       5.2.1.1 Financial Overview
  114.       5.2.1.2 Products Offered
  115.       5.2.1.3 Key Developments
  116.       5.2.1.4 SWOT Analysis
  117.       5.2.1.5 Key Strategies
  118.     5.2.2 Bachem Holding AG (CH)
  119.       5.2.2.1 Financial Overview
  120.       5.2.2.2 Products Offered
  121.       5.2.2.3 Key Developments
  122.       5.2.2.4 SWOT Analysis
  123.       5.2.2.5 Key Strategies
  124.     5.2.3 Cypress Pharmaceutical, Inc. (US)
  125.       5.2.3.1 Financial Overview
  126.       5.2.3.2 Products Offered
  127.       5.2.3.3 Key Developments
  128.       5.2.3.4 SWOT Analysis
  129.       5.2.3.5 Key Strategies
  130.     5.2.4 Genomatica, Inc. (US)
  131.       5.2.4.1 Financial Overview
  132.       5.2.4.2 Products Offered
  133.       5.2.4.3 Key Developments
  134.       5.2.4.4 SWOT Analysis
  135.       5.2.4.5 Key Strategies
  136.     5.2.5 Hefei Tianheng Chemical Co., Ltd. (CN)
  137.       5.2.5.1 Financial Overview
  138.       5.2.5.2 Products Offered
  139.       5.2.5.3 Key Developments
  140.       5.2.5.4 SWOT Analysis
  141.       5.2.5.5 Key Strategies
  142.     5.2.6 Jiangsu Hengrui Medicine Co., Ltd. (CN)
  143.       5.2.6.1 Financial Overview
  144.       5.2.6.2 Products Offered
  145.       5.2.6.3 Key Developments
  146.       5.2.6.4 SWOT Analysis
  147.       5.2.6.5 Key Strategies
  148.     5.2.7 Merck KGaA (DE)
  149.       5.2.7.1 Financial Overview
  150.       5.2.7.2 Products Offered
  151.       5.2.7.3 Key Developments
  152.       5.2.7.4 SWOT Analysis
  153.       5.2.7.5 Key Strategies
  154.     5.2.8 Pepscan Therapeutics B.V. (NL)
  155.       5.2.8.1 Financial Overview
  156.       5.2.8.2 Products Offered
  157.       5.2.8.3 Key Developments
  158.       5.2.8.4 SWOT Analysis
  159.       5.2.8.5 Key Strategies
  160.     5.2.9 Scripps Research Institute (US)
  161.       5.2.9.1 Financial Overview
  162.       5.2.9.2 Products Offered
  163.       5.2.9.3 Key Developments
  164.       5.2.9.4 SWOT Analysis
  165.       5.2.9.5 Key Strategies
  166.   5.3 Appendix
  167.     5.3.1 References
  168.     5.3.2 Related Reports
  169. 6 LIST OF FIGURES
  170.   6.1 MARKET SYNOPSIS
  171.   6.2 NORTH AMERICA MARKET ANALYSIS
  172.   6.3 US MARKET ANALYSIS BY TYPE
  173.   6.4 US MARKET ANALYSIS BY APPLICATION
  174.   6.5 US MARKET ANALYSIS BY END-USER
  175.   6.6 CANADA MARKET ANALYSIS BY TYPE
  176.   6.7 CANADA MARKET ANALYSIS BY APPLICATION
  177.   6.8 CANADA MARKET ANALYSIS BY END-USER
  178.   6.9 EUROPE MARKET ANALYSIS
  179.   6.10 GERMANY MARKET ANALYSIS BY TYPE
  180.   6.11 GERMANY MARKET ANALYSIS BY APPLICATION
  181.   6.12 GERMANY MARKET ANALYSIS BY END-USER
  182.   6.13 UK MARKET ANALYSIS BY TYPE
  183.   6.14 UK MARKET ANALYSIS BY APPLICATION
  184.   6.15 UK MARKET ANALYSIS BY END-USER
  185.   6.16 FRANCE MARKET ANALYSIS BY TYPE
  186.   6.17 FRANCE MARKET ANALYSIS BY APPLICATION
  187.   6.18 FRANCE MARKET ANALYSIS BY END-USER
  188.   6.19 RUSSIA MARKET ANALYSIS BY TYPE
  189.   6.20 RUSSIA MARKET ANALYSIS BY APPLICATION
  190.   6.21 RUSSIA MARKET ANALYSIS BY END-USER
  191.   6.22 ITALY MARKET ANALYSIS BY TYPE
  192.   6.23 ITALY MARKET ANALYSIS BY APPLICATION
  193.   6.24 ITALY MARKET ANALYSIS BY END-USER
  194.   6.25 SPAIN MARKET ANALYSIS BY TYPE
  195.   6.26 SPAIN MARKET ANALYSIS BY APPLICATION
  196.   6.27 SPAIN MARKET ANALYSIS BY END-USER
  197.   6.28 REST OF EUROPE MARKET ANALYSIS BY TYPE
  198.   6.29 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
  199.   6.30 REST OF EUROPE MARKET ANALYSIS BY END-USER
  200.   6.31 APAC MARKET ANALYSIS
  201.   6.32 CHINA MARKET ANALYSIS BY TYPE
  202.   6.33 CHINA MARKET ANALYSIS BY APPLICATION
  203.   6.34 CHINA MARKET ANALYSIS BY END-USER
  204.   6.35 INDIA MARKET ANALYSIS BY TYPE
  205.   6.36 INDIA MARKET ANALYSIS BY APPLICATION
  206.   6.37 INDIA MARKET ANALYSIS BY END-USER
  207.   6.38 JAPAN MARKET ANALYSIS BY TYPE
  208.   6.39 JAPAN MARKET ANALYSIS BY APPLICATION
  209.   6.40 JAPAN MARKET ANALYSIS BY END-USER
  210.   6.41 SOUTH KOREA MARKET ANALYSIS BY TYPE
  211.   6.42 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
  212.   6.43 SOUTH KOREA MARKET ANALYSIS BY END-USER
  213.   6.44 MALAYSIA MARKET ANALYSIS BY TYPE
  214.   6.45 MALAYSIA MARKET ANALYSIS BY APPLICATION
  215.   6.46 MALAYSIA MARKET ANALYSIS BY END-USER
  216.   6.47 THAILAND MARKET ANALYSIS BY TYPE
  217.   6.48 THAILAND MARKET ANALYSIS BY APPLICATION
  218.   6.49 THAILAND MARKET ANALYSIS BY END-USER
  219.   6.50 INDONESIA MARKET ANALYSIS BY TYPE
  220.   6.51 INDONESIA MARKET ANALYSIS BY APPLICATION
  221.   6.52 INDONESIA MARKET ANALYSIS BY END-USER
  222.   6.53 REST OF APAC MARKET ANALYSIS BY TYPE
  223.   6.54 REST OF APAC MARKET ANALYSIS BY APPLICATION
  224.   6.55 REST OF APAC MARKET ANALYSIS BY END-USER
  225.   6.56 SOUTH AMERICA MARKET ANALYSIS
  226.   6.57 BRAZIL MARKET ANALYSIS BY TYPE
  227.   6.58 BRAZIL MARKET ANALYSIS BY APPLICATION
  228.   6.59 BRAZIL MARKET ANALYSIS BY END-USER
  229.   6.60 MEXICO MARKET ANALYSIS BY TYPE
  230.   6.61 MEXICO MARKET ANALYSIS BY APPLICATION
  231.   6.62 MEXICO MARKET ANALYSIS BY END-USER
  232.   6.63 ARGENTINA MARKET ANALYSIS BY TYPE
  233.   6.64 ARGENTINA MARKET ANALYSIS BY APPLICATION
  234.   6.65 ARGENTINA MARKET ANALYSIS BY END-USER
  235.   6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
  236.   6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
  237.   6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER
  238.   6.69 MEA MARKET ANALYSIS
  239.   6.70 GCC COUNTRIES MARKET ANALYSIS BY TYPE
  240.   6.71 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
  241.   6.72 GCC COUNTRIES MARKET ANALYSIS BY END-USER
  242.   6.73 SOUTH AFRICA MARKET ANALYSIS BY TYPE
  243.   6.74 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
  244.   6.75 SOUTH AFRICA MARKET ANALYSIS BY END-USER
  245.   6.76 REST OF MEA MARKET ANALYSIS BY TYPE
  246.   6.77 REST OF MEA MARKET ANALYSIS BY APPLICATION
  247.   6.78 REST OF MEA MARKET ANALYSIS BY END-USER
  248.   6.79 KEY BUYING CRITERIA OF HEALTHCARE
  249.   6.80 RESEARCH PROCESS OF MRFR
  250.   6.81 DRO ANALYSIS OF HEALTHCARE
  251.   6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  252.   6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  253.   6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
  254.   6.85 HEALTHCARE, BY TYPE, 2024 (% SHARE)
  255.   6.86 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
  256.   6.87 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  257.   6.88 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  258.   6.89 HEALTHCARE, BY END-USER, 2024 (% SHARE)
  259.   6.90 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Billion)
  260.   6.91 BENCHMARKING OF MAJOR COMPETITORS
  261. 7 LIST OF TABLES
  262.   7.1 LIST OF ASSUMPTIONS
  263.     7.1.1
  264.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  265.     7.2.1 BY TYPE, 2025-2035 (USD Billion)
  266.     7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
  267.     7.2.3 BY END-USER, 2025-2035 (USD Billion)
  268.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  269.     7.3.1 BY TYPE, 2025-2035 (USD Billion)
  270.     7.3.2 BY APPLICATION, 2025-2035 (USD Billion)
  271.     7.3.3 BY END-USER, 2025-2035 (USD Billion)
  272.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  273.     7.4.1 BY TYPE, 2025-2035 (USD Billion)
  274.     7.4.2 BY APPLICATION, 2025-2035 (USD Billion)
  275.     7.4.3 BY END-USER, 2025-2035 (USD Billion)
  276.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  277.     7.5.1 BY TYPE, 2025-2035 (USD Billion)
  278.     7.5.2 BY APPLICATION, 2025-2035 (USD Billion)
  279.     7.5.3 BY END-USER, 2025-2035 (USD Billion)
  280.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  281.     7.6.1 BY TYPE, 2025-2035 (USD Billion)
  282.     7.6.2 BY APPLICATION, 2025-2035 (USD Billion)
  283.     7.6.3 BY END-USER, 2025-2035 (USD Billion)
  284.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  285.     7.7.1 BY TYPE, 2025-2035 (USD Billion)
  286.     7.7.2 BY APPLICATION, 2025-2035 (USD Billion)
  287.     7.7.3 BY END-USER, 2025-2035 (USD Billion)
  288.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  289.     7.8.1 BY TYPE, 2025-2035 (USD Billion)
  290.     7.8.2 BY APPLICATION, 2025-2035 (USD Billion)
  291.     7.8.3 BY END-USER, 2025-2035 (USD Billion)
  292.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  293.     7.9.1 BY TYPE, 2025-2035 (USD Billion)
  294.     7.9.2 BY APPLICATION, 2025-2035 (USD Billion)
  295.     7.9.3 BY END-USER, 2025-2035 (USD Billion)
  296.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  297.     7.10.1 BY TYPE, 2025-2035 (USD Billion)
  298.     7.10.2 BY APPLICATION, 2025-2035 (USD Billion)
  299.     7.10.3 BY END-USER, 2025-2035 (USD Billion)
  300.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  301.     7.11.1 BY TYPE, 2025-2035 (USD Billion)
  302.     7.11.2 BY APPLICATION, 2025-2035 (USD Billion)
  303.     7.11.3 BY END-USER, 2025-2035 (USD Billion)
  304.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  305.     7.12.1 BY TYPE, 2025-2035 (USD Billion)
  306.     7.12.2 BY APPLICATION, 2025-2035 (USD Billion)
  307.     7.12.3 BY END-USER, 2025-2035 (USD Billion)
  308.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  309.     7.13.1 BY TYPE, 2025-2035 (USD Billion)
  310.     7.13.2 BY APPLICATION, 2025-2035 (USD Billion)
  311.     7.13.3 BY END-USER, 2025-2035 (USD Billion)
  312.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  313.     7.14.1 BY TYPE, 2025-2035 (USD Billion)
  314.     7.14.2 BY APPLICATION, 2025-2035 (USD Billion)
  315.     7.14.3 BY END-USER, 2025-2035 (USD Billion)
  316.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  317.     7.15.1 BY TYPE, 2025-2035 (USD Billion)
  318.     7.15.2 BY APPLICATION, 2025-2035 (USD Billion)
  319.     7.15.3 BY END-USER, 2025-2035 (USD Billion)
  320.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  321.     7.16.1 BY TYPE, 2025-2035 (USD Billion)
  322.     7.16.2 BY APPLICATION, 2025-2035 (USD Billion)
  323.     7.16.3 BY END-USER, 2025-2035 (USD Billion)
  324.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  325.     7.17.1 BY TYPE, 2025-2035 (USD Billion)
  326.     7.17.2 BY APPLICATION, 2025-2035 (USD Billion)
  327.     7.17.3 BY END-USER, 2025-2035 (USD Billion)
  328.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  329.     7.18.1 BY TYPE, 2025-2035 (USD Billion)
  330.     7.18.2 BY APPLICATION, 2025-2035 (USD Billion)
  331.     7.18.3 BY END-USER, 2025-2035 (USD Billion)
  332.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  333.     7.19.1 BY TYPE, 2025-2035 (USD Billion)
  334.     7.19.2 BY APPLICATION, 2025-2035 (USD Billion)
  335.     7.19.3 BY END-USER, 2025-2035 (USD Billion)
  336.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  337.     7.20.1 BY TYPE, 2025-2035 (USD Billion)
  338.     7.20.2 BY APPLICATION, 2025-2035 (USD Billion)
  339.     7.20.3 BY END-USER, 2025-2035 (USD Billion)
  340.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  341.     7.21.1 BY TYPE, 2025-2035 (USD Billion)
  342.     7.21.2 BY APPLICATION, 2025-2035 (USD Billion)
  343.     7.21.3 BY END-USER, 2025-2035 (USD Billion)
  344.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  345.     7.22.1 BY TYPE, 2025-2035 (USD Billion)
  346.     7.22.2 BY APPLICATION, 2025-2035 (USD Billion)
  347.     7.22.3 BY END-USER, 2025-2035 (USD Billion)
  348.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  349.     7.23.1 BY TYPE, 2025-2035 (USD Billion)
  350.     7.23.2 BY APPLICATION, 2025-2035 (USD Billion)
  351.     7.23.3 BY END-USER, 2025-2035 (USD Billion)
  352.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  353.     7.24.1 BY TYPE, 2025-2035 (USD Billion)
  354.     7.24.2 BY APPLICATION, 2025-2035 (USD Billion)
  355.     7.24.3 BY END-USER, 2025-2035 (USD Billion)
  356.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  357.     7.25.1 BY TYPE, 2025-2035 (USD Billion)
  358.     7.25.2 BY APPLICATION, 2025-2035 (USD Billion)
  359.     7.25.3 BY END-USER, 2025-2035 (USD Billion)
  360.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  361.     7.26.1 BY TYPE, 2025-2035 (USD Billion)
  362.     7.26.2 BY APPLICATION, 2025-2035 (USD Billion)
  363.     7.26.3 BY END-USER, 2025-2035 (USD Billion)
  364.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  365.     7.27.1 BY TYPE, 2025-2035 (USD Billion)
  366.     7.27.2 BY APPLICATION, 2025-2035 (USD Billion)
  367.     7.27.3 BY END-USER, 2025-2035 (USD Billion)
  368.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  369.     7.28.1 BY TYPE, 2025-2035 (USD Billion)
  370.     7.28.2 BY APPLICATION, 2025-2035 (USD Billion)
  371.     7.28.3 BY END-USER, 2025-2035 (USD Billion)
  372.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  373.     7.29.1 BY TYPE, 2025-2035 (USD Billion)
  374.     7.29.2 BY APPLICATION, 2025-2035 (USD Billion)
  375.     7.29.3 BY END-USER, 2025-2035 (USD Billion)
  376.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  377.     7.30.1 BY TYPE, 2025-2035 (USD Billion)
  378.     7.30.2 BY APPLICATION, 2025-2035 (USD Billion)
  379.     7.30.3 BY END-USER, 2025-2035 (USD Billion)
  380.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  381.     7.31.1
  382.   7.32 ACQUISITION/PARTNERSHIP
  383.     7.32.1

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

  • D-Amino Acids & Derivatives
  • DL-Amino Acids & Derivatives
  • B-Amino Acids & Derivatives
  • Cyclic Amino Acids & Derivatives
  • L-Amino Acid Derivatives
  • Gamma-Amino Butyric Acid (GABA)
  • Gamma-Amino-Beta-Hydroxybutyric Acid (GABOB)
  • Synthetic-Amino Acids
  • Others

Healthcare By Application (USD Billion, 2025-2035)

  • Liver Diseases
  • Cancer
  • Inflammatory Diseases
  • Genetic Diseases

Healthcare By End-User (USD Billion, 2025-2035)

  • Pharmaceutical & Biotechnological Companies
  • Research Laboratories

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓